Structural insights into selective small molecule activation of PKG1α.

Autor: Metwally E; Modeling and Informatics, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA. essam.metwally@merck.com., Mak V; Discovery Chemistry, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Soriano A; Quantitative Biosciences, MRL, Merck & Co., Inc., Kenilworth, NJ, USA., Zebisch M; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK., Silvestre HL; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK., McEwan PA; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK., Ermakov G; Discovery Bioanalytics, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Beaumont M; Discovery Bioanalytics, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Tawa P; Quantitative Biosciences, MRL, Merck & Co., Inc., Kenilworth, NJ, USA., Barker JJ; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK., Yen R; Discovery Chemistry, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Patel A; Discovery Chemistry, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Lim YH; Discovery Chemistry, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Healy D; Discovery Biology, MRL, Merck & Co., Inc., Boston, MA, USA., Hanisak J; Discovery Chemistry, MRL, Merck & Co., Inc., Kenilworth, NJ, USA., Cheng AC; Modeling and Informatics, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Greshock T; Discovery Chemistry, MRL, Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, CA, USA., Fischmann TO; Protein and Structural Chemistry, MRL, Merck & Co., Inc., Kenilworth, NJ, USA. thierry.fischmann@merck.com.
Jazyk: angličtina
Zdroj: Communications biology [Commun Biol] 2023 Jul 31; Vol. 6 (1), pp. 798. Date of Electronic Publication: 2023 Jul 31.
DOI: 10.1038/s42003-023-05095-4
Abstrakt: cGMP-dependent protein kinase I-α (PKG1α) is a target for pulmonary arterial hypertension due to its role in the regulation of smooth muscle function. While most work has focused on regulation of cGMP turnover, we recently described several small molecule tool compounds which were capable of activating PKG1α via a cGMP independent pathway. Selected molecules were crystallized in the presence of PKG1α and were found to bind to an allosteric site proximal to the low-affinity nucleotide binding domain. These molecules act to displace the switch helix and cause activation of PKG1α representing a new mechanism for the activation and control of this critical therapeutic path. The described structures are vital to understanding the function and control of this key regulatory pathway.
(© 2023. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.)
Databáze: MEDLINE
Externí odkaz: